secwatch.observer — SEC 8-K summary
======================================

Issuer:     VOLITIONRX LTD (VNRX)
CIK:        0000093314
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001477932-25-002227
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M
----------------------------------------------------------------

- Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.
- Operating expenses down 23% YoY; post-year-end raised $2.3M equity and $1.8M non-dilutive funding.
- Sold ~120,000 Nu.Q Vet Cancer Tests; available in 20+ countries; active commercial discussions for human diagnostics.
- Goal to be cash neutral in 2025 via licensing receipts and revenue.
- Board strengthened with new Chair Timothy Still and Director Dr. Ethel Rubin.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/93314/000147793225002227/0001477932-25-002227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/93314/000147793225002227/vnrx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001477932-25-002227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer